Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lofepramine/phenylalanine - MultiCell Technologies

Drug Profile

Lofepramine/phenylalanine - MultiCell Technologies

Alternative Names: L-phenylalanine/Lofepramine; LAX-202; Lofepramine/L-phenylalanine; MCT-125; Phenylalanine/lofepramine

Latest Information Update: 03 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Class Dibenzazepines; Essential amino acids; Neuropsychotherapeutics; Tricyclic antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Fatigue

Most Recent Events

  • 03 Sep 2015 Lofepramine/phenylalanine is still in phase-II development for Fatigue
  • 02 Nov 2010 MultiCell receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for MCT 125 development in Fatigue
  • 03 Jan 2006 Data from a media release have been added to the Neurological Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top